Vor Biopharma (VOR) Stock Forecast, Price Target & Predictions
VOR Stock Forecast
Vor Biopharma stock forecast is as follows: an average price target of $6.00 (represents a 591.80% upside from VOR’s last price of $0.87) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
VOR Price Target
The average price target for Vor Biopharma (VOR) is $6.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 591.80% upside from VOR's last price of $0.87.
VOR Analyst Ratings
According to 4 Wall Street analysts, Vor Biopharma's rating consensus is 'Buy'. The analyst rating breakdown for VOR stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Vor Biopharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Apr 27, 2022 | Goldman Sachs | $6.00 | $5.60 | 7.14% | 591.80% |
The latest Vor Biopharma stock forecast, released on Apr 27, 2022 by Goldman Sachs company, set a price target of $6.00, which represents a 7.14% increase from the stock price at the time of the forecast ($5.60), and a 591.80% increase from VOR last price ($0.87).
Vor Biopharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.87 | $0.87 | $0.87 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Vor Biopharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Vor Biopharma's last price of $0.87. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 14, 2024 | Barclays | Overweight | Overweight | Hold |
| Nov 14, 2022 | Oppenheimer | Outperform | Outperform | Hold |
| Jul 27, 2022 | Wedbush | Outperform | Initialise |
Vor Biopharma's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave VOR a "Buy" rating, the same as its previous rate.
Vor Biopharma Financial Forecast
Vor Biopharma Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vor Biopharma's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. VOR's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Vor Biopharma EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict VOR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Vor Biopharma's previous annual EBITDA (undefined) of $NaN.
Vor Biopharma Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-24.60M | $-20.81M | $-20.31M | $-20.14M | $-22.26M | $-27.54M | $-28.53M |
| High Forecast | $-24.60M | $-20.81M | $-20.31M | $-17.16M | $-13.91M | $-27.54M | $-28.53M |
| Low Forecast | $-24.60M | $-20.81M | $-20.31M | $-22.38M | $-26.43M | $-27.54M | $-28.53M |
| Surprise % | - | - | - | - | - | - | - |
Vor Biopharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. VOR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Vor Biopharma SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Vor Biopharma's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to VOR last annual SG&A of $NaN (undefined).
Vor Biopharma EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.36 | $-0.30 | $-0.30 | $-0.29 | $-0.33 | $-0.40 | $-0.42 |
| High Forecast | $-0.36 | $-0.30 | $-0.30 | $-0.25 | $-0.20 | $-0.40 | $-0.42 |
| Low Forecast | $-0.36 | $-0.30 | $-0.30 | $-0.33 | $-0.39 | $-0.40 | $-0.42 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Vor Biopharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to VOR previous annual EPS of $NaN (undefined).
Vor Biopharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACET | Adicet Bio | $0.96 | $32.50 | 3285.42% | Buy |
| VTYX | Ventyx Biosciences | $2.37 | $33.86 | 1328.69% | Buy |
| STTK | Shattuck Labs | $1.15 | $12.00 | 943.48% | Hold |
| VOR | Vor Biopharma | $0.98 | $6.00 | 512.24% | Buy |
| AUTL | Autolus Therapeutics | $2.49 | $7.60 | 205.22% | Buy |
| CGEM | Cullinan Oncology | $11.49 | $34.00 | 195.91% | Buy |
| LYRA | Lyra Therapeutics | $0.18 | $0.50 | 177.78% | Hold |
| FHTX | Foghorn Therapeutics | $5.51 | $14.00 | 154.08% | Buy |
| ERAS | Erasca | $2.63 | $6.00 | 128.14% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| BOLT | Bolt Biotherapeutics | $0.54 | $1.00 | 85.19% | Hold |
| KNSA | Kiniksa Pharmaceuticals | $20.49 | $37.50 | 83.02% | Buy |
| DSGN | Design Therapeutics | $6.25 | $9.67 | 54.72% | Buy |
| NRIX | Nurix Therapeutics | $21.18 | $32.67 | 54.25% | Buy |
| EWTX | Edgewise Therapeutics | $30.17 | $46.25 | 53.30% | Buy |
| KYMR | Kymera Therapeutics | $42.30 | $58.60 | 38.53% | Buy |
| ACLX | Arcellx | $82.03 | $111.60 | 36.05% | Buy |
| NUVL | Nuvalent | $88.10 | $114.80 | 30.31% | Buy |